Leadership and innovation in Companion Diagnostics
Since launching the first FDA-approved companion diagnostic (CDx) over 25 years ago, Agilent continues to deliver CDx solutions in close collaboration with our pharma partners worldwide.
Accelerate your CDx development program by leveraging our broad technical expertise, global infrastructure, and decades of proven experience.
Visit us in booth 36076 to discuss our CDx capabilities.
Choose a partner that understands the promise of precision medicine and has a successful legacy of biomarker assay and CDx development.
Streamlined process from early biomarker discovery to full CDx development and commercialization.
Select the right therapy every time, rapidly, and with high confidence with our portfolio of FDA-approved CDx solutions.
Digital pathology powered by end-to-end expertise
For the first time, experience the power of DNA and methylation in one target enrichment workflow. Capture DNA variants and methylation alterations from a single input, no sample splitting required. The novel, high-performance workflow offers multiomics capabilities and outstanding fidelity, turnaround time, and ease of use.
SureSelect Cancer CGP assay offers comprehensive genomic profiling for solid tumors. Powered by SureSelect XT HS2, the assay features fast hybridization, low sample input, enzymatic fragmentation, and a one-day workflow.
Drive productivity and reproducibility for NGS library preparation and target enrichment with Agilent automation platforms in a comprehensive and versatile workflow.
Contact us today and talk to one of our precision medicine experts.
**For Research Use Only. Not for use in diagnostic procedures.
This information is subject to change without notice.
D0131755_1.00